| Theme | Hepatitis B : Towards the Elimination | |
|---|---|---|
| Title | The Incidence of Hepatocellular Carcinoma in Hepatitis B Patients Treated with Nucleos(t)ide Analogues | |
| Publish Date | 2016/03 | |
| Author | Tetsuya Hosaka | Department of Hepatology, Toranomon Hospital |
| [ Summary ] | Nucleos(t)ide analogues (NAs) are known to reduce hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B (CHB) patients, but do not eliminate HCC risk. The serum hepatitis B core‒related antigen (HBcrAg) has been known to be a surrogate marker of intrahepatic covalently closed circular DNA (cccDNA). Patients with high on‒treatment HBcrAg levels were likely to develop HCC despite long‒term NA treatment. | |